Small particle drug-eluting beads-transarterial chemoembolization combined with targeted therapy in the clinical treatment of unresectable liver cancer

Table 4 Comparison of adverse reaction occurrence between the two groups, n (%)

Adverse reaction	Control group, n = 36	Joint group, n = 38	χ2	P value
Embolism syndrome	0 (0)	2 (5.26)
Fatigue	1 (2.78)	1 (2.63)
Abnormal liver function	2 (5.56)	1 (2.63)
Rash	1 (2.78)	2 (5.26)
Bone marrow suppression	0 (0)	1 (2.63)
Gastrointestinal reaction	2 (5.56)	2 (5.26)
Hand-foot syndrome	1 (2.78)	2 (5.26)
Total incidence	7 (19.44)	11 (28.95)	0.907	0.341